Apyx Medical (NASDAQ: APYX) revises board committees, names audit expert

Q: What board governance change did Apyx Medical (APYX) disclose on July 24, 2026?

Apyx Medical (APYX) disclosed that its Board of Directors reconstituted the membership and chairs of its standing committees . This governance update reshapes which directors serve on key Board committees and who leads them, potentially affecting oversight of audit, compensation, and other core responsibilities.

Q: Which Apyx Medical (APYX) directors were deemed independent in the July 2026 update?

The Board determined that Mr. Waldman, Ms. Baylor-Henry, and Ms. Levine are independent under Nasdaq Global Select Market and SEC rules. These independence determinations support compliance with listing standards for committee composition and help ensure objective oversight of management and financial reporting.

Q: Who is Apyx Medical’s (APYX) audit committee financial expert as of July 2026?

The Board determined that Mr. Waldman qualifies as an "audit committee financial expert" under SEC regulations. This designation indicates he has the financial sophistication and experience the SEC expects for enhanced oversight of accounting, internal controls, and financial reporting on the audit committee.

Q: Will Apyx Medical (APYX) Executive Chairman Stavros Vizirgianakis serve on any Board committees?

No. In light of his role as Executive Chairman effective June 11, 2026 , Stavros Vizirgianakis will not serve on any Board committee. This separation keeps him off standing committees while he continues to lead the Board and maintain his executive responsibilities at the company.

Q: What stock exchange lists Apyx Medical (APYX) and under what trading symbol?

Apyx Medical’s common stock is listed on the Nasdaq Global Select Market under the symbol "APYX" . This listing subjects the company to Nasdaq’s corporate governance and independence standards, which the Board referenced in its committee independence determinations.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

On July 24, 2026, Apyx Medical Corporation reported that its Board of Directors reconstituted the membership and chairs of its standing committees.

Following his appointment as Executive Chairman effective June 11, 2026, Stavros Vizirgianakis will not serve on any Board committee. The Board determined that Mr. Waldman, Ms. Baylor-Henry, and Ms. Levine are independent under applicable Nasdaq Global Select Market and SEC rules and that Mr. Waldman qualifies as an audit committee financial expert under SEC regulations.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Terms

audit committee financial expert, Emerging growth company, Nasdaq Global Select Market

3 terms

audit committee financial expert financial

"Mr. Waldman qualifies as an “audit committee financial expert” as defined"

A person on a company’s board who has deep knowledge of accounting, financial reporting and auditing, able to understand and question the books, controls and audit work like a trained mechanic inspecting an engine. Investors care because that expertise helps spot errors, weaknesses or misleading statements early, improving the likelihood that financial reports are accurate and reducing the risk of surprises that can hurt a company’s value.

Emerging growth company regulatory

"405 of this chapter) or Rule 12b-2 of the Securities Exchange Act… Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Nasdaq Global Select Market financial

"independent under the applicable rules of The Nasdaq Global Select Market"

A Nasdaq Global Select Market listing is the highest tier of stocks on the Nasdaq exchange, reserved for companies that meet the strictest financial, reporting and governance standards. For investors, it acts like a premium quality label—signaling larger, more transparent and better-governed companies that tend to offer greater liquidity and lower perceived risk compared with lower-tier listings, making it easier to buy, sell and evaluate shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

Available on EDGAR 07/24/2026 - 05:18 PM Accepted by SEC EDGAR 07/24/2026 - 05:18 PM

FAQ

What board governance change did Apyx Medical (APYX) disclose on July 24, 2026?

Apyx Medical (APYX) disclosed that its Board of Directors reconstituted the membership and chairs of its standing committees. This governance update reshapes which directors serve on key Board committees and who leads them, potentially affecting oversight of audit, compensation, and other core responsibilities.

Which Apyx Medical (APYX) directors were deemed independent in the July 2026 update?

The Board determined that Mr. Waldman, Ms. Baylor-Henry, and Ms. Levine are independent under Nasdaq Global Select Market and SEC rules. These independence determinations support compliance with listing standards for committee composition and help ensure objective oversight of management and financial reporting.

Who is Apyx Medical’s (APYX) audit committee financial expert as of July 2026?

The Board determined that Mr. Waldman qualifies as an "audit committee financial expert" under SEC regulations. This designation indicates he has the financial sophistication and experience the SEC expects for enhanced oversight of accounting, internal controls, and financial reporting on the audit committee.

Will Apyx Medical (APYX) Executive Chairman Stavros Vizirgianakis serve on any Board committees?

No. In light of his role as Executive Chairman effective June 11, 2026, Stavros Vizirgianakis will not serve on any Board committee. This separation keeps him off standing committees while he continues to lead the Board and maintain his executive responsibilities at the company.

What stock exchange lists Apyx Medical (APYX) and under what trading symbol?

Apyx Medical’s common stock is listed on the Nasdaq Global Select Market under the symbol "APYX". This listing subjects the company to Nasdaq’s corporate governance and independence standards, which the Board referenced in its committee independence determinations.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

July 24, 2026

Date of Report (date of earliest event reported)

APYX MEDICAL CORPORATION

(Exact name of registrant as specified in its charter)

Delaware

001-31885

11-2644611

(State or other jurisdiction

of incorporation or organization)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

5115 Ulmerton Road, Clearwater, Florida 33760

(Address of principal executive offices, zip code)

(727) 384-2323

Registrant’s telephone number, including area code

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		APYX		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01.

Other Events.

On July 24, 2026, the Board of Directors (the “Board”) of Apyx Medical Corporation (the “Company”) reconstituted the membership and chairs of its standing committees as described below.

The membership and chairs of the reconstituted committees are as follows:

Audit Committee: Lawrence J. Waldman (Chair), Minnie Baylor-Henry, and Wendy Levine;

Governance and Nominating Committee: Minnie Baylor-Henry (Chair), Lawrence J. Waldman, and Wendy Levine;

Regulatory Compliance Committee: Minnie Baylor-Henry (Chair), Lawrence J. Waldman, and Wendy Levine; and

Compensation Committee: Wendy Levine (Chair), Lawrence J. Waldman, and Minnie Baylor-Henry.

In light of his appointment as Executive Chairman of the Board (effective June 11, 2026), Stavros Vizirgianakis will not serve on any committee of the Board.

The Board has determined that each of Mr. Waldman, Ms. Baylor-Henry, and Ms. Levine is “independent” under the applicable rules of The Nasdaq Global Select Market and the Securities and Exchange Commission. The Board has further determined that Mr. Waldman qualifies as an “audit committee financial expert” as defined by the rules and regulations of the Securities and Exchange Commission.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
104		Cover Page Interactive Data File embedded within the Inline XBRL document

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	APYX MEDICAL CORPORATION

Date: July 24, 2026	By:	/s/ Matthew Hill
	Name:	Matthew Hill
	Title:	Chief Financial Officer, Secretary and Treasurer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents